Expanding Vaccine Portfolio Panacea Biotec’s leadership in innovative vaccines like the fully liquid Hexavalent and Pentavalent vaccines, along with a high-impact pipeline including pneumococcal and dengue vaccines, presents opportunities to collaborate with government health programs and global agencies seeking immunization solutions.

Global Reach & Reputation With products available in over 145 countries and trusted partnerships with WHO, GAVI, and UNICEF, the company is well-positioned to expand its supply chain and distribution channels, especially for large-scale immunization initiatives and emerging markets.

Strategic Collaborations Recent contracts with UNICEF and the Central Medical Services Society highlight ongoing demand for polio vaccines and other immunizations, creating potential for customized vaccine development and capacity expansion to meet increasing international procurement needs.

Research & Innovation Panacea’s focus on R&D, exemplified by their new vaccine launches and partnerships with research institutions like ICMR, enables sales teams to target government and private sector clients seeking innovative health solutions and contract manufacturing opportunities.

Manufacturing Capacity Supported by recent investments and approvals like US FDA and WHO prequalification, the company’s scalable manufacturing capabilities position it to respond to rising global demand for affordable, high-quality vaccines and pharmaceutical products.